{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-24-000165","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.026250+00:00","generated_at":"2026-05-30T02:13:58.923063+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Centessa discontinues SerpinPC, launches ORX750 Phase 2a, Q3 net loss $42.6M","bullets":["Additional interim Phase 1 data for ORX750 in sleep-deprived volunteers showed statistically significant increase in wakefulness at all doses with favorable safety; Phase 2a initiated in NT1, NT2, IH.","Discontinued SerpinPC development after interim analysis; net savings of ~$200M reallocated to OX2R agonist franchise.","Cash $518.4M as of Sept 30, 2024; expected to fund operations into mid-2027.","Completed upsized public offering in Sept 2024 resulting in net proceeds of ~$242.7M.","Advancing ORX142 and ORX489 in IND-enabling studies; clinical data expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-24-000165","json":"https://secwatch.observer/filing/0001847903-24-000165.json","markdown":"https://secwatch.observer/filing/0001847903-24-000165.md","text":"https://secwatch.observer/filing/0001847903-24-000165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790324000165/0001847903-24-000165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790324000165/cnta-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:13:58.923063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}